SY 1365

Drug Profile

SY 1365

Alternative Names: SY-1365

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syros Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Cancer; Haematological malignancies; Ovarian cancer

Most Recent Events

  • 16 Apr 2018 Pharmacodynamics data from preclinical studies in Ovarian cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2018)
  • 10 Dec 2017 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at the 59th American Society of Hematology Annual Meeting (ASH-Hem-2017)
  • 07 Dec 2017 Pharmacodynamics data from a preclinical study in Cancer released by Syros
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top